S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

GILD Gilead Sciences Inc

86.72

-0.64 (-0.73%)

Oct 18 2024 - Closed

Delayed by 15 minutes

Gilead wins FDA approval for Yescarta in follicular lymphoma

To read the full story on Seeking Alpha, click here.

Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2024 to Oct 2024

Click Here for more Gilead Sciences Charts.

Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Oct 2023 to Oct 2024

Click Here for more Gilead Sciences Charts.

Gilead Sciences Inc News

Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
Wednesday 9 October 2024 (1 week ago) • Business Wire

Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
Wednesday 9 October 2024 (1 week ago) • Business Wire

Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
Monday 7 October 2024 (2 weeks ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 2 October 2024 (2 weeks ago) • Edgar (US Regulatory)

Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
Wednesday 2 October 2024 (2 weeks ago) • PR Newswire (US)

Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
Wednesday 2 October 2024 (2 weeks ago) • PR Newswire (US)

Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
Wednesday 2 October 2024 (2 weeks ago) • Business Wire

Form 144 - Report of proposed sale of securities
Tuesday 1 October 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 13 September 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 13 September 2024 (1 month ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Thursday 12 September 2024 (1 month ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Thursday 12 September 2024 (1 month ago) • Edgar (US Regulatory)

More Gilead Sciences Inc News Articles

Vitalharvest Freehold

Erste Group Bank

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions